Business

Corealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation Development

Financial Post · September 23, 2026 at 9:39 a.m.

LAVAL, Quebec -- Corealis Pharma (“Corealis”) and PhinC Group (“PhinC”) have announced a strategic collaboration to integrate physiologically based biopharmaceutics modeling (PBBM) and physiologically based pharmacokinetic (PBPK) modeling directly into oral solid dosage form development.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Corealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation Development

More from Financial Post

Cambria Gold Mines Intersects 98.56 g/t Gold over 8.2 Metres at the Silver Coin Deposit, Premier Gold Project

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future

Royal Canadian Legion statement: CFB Wainwright tragedy

The Plastic Surgery Foundation appoints Sara R. Dickie, MD, as President

More in Business

Cambria Gold Mines Intersects 98.56 g/t Gold over 8.2 Metres at the Silver Coin Deposit, Premier Gold Project

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future

Royal Canadian Legion statement: CFB Wainwright tragedy

The Plastic Surgery Foundation appoints Sara R. Dickie, MD, as President

Lynn A. Damitz, MD, FACS, named President of the American Society of Plastic Surgeons

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery